2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult

Cited by (1,000)

Items 701–800 of 1,000

1. Non-HDL-C goals based on the distribution of population percentiles in ELSA-Brasil: Is it time to change?
   Fabiano A. Brito, William Pedrosa, Chams Bicalho Maluf, Rodrigo Citton Padilha dos Reis, L Fedeli, Cristina Dickie de Castilhos, Sandhi Maria Barreto, Pedro Guatimosim Vidigal · 2018 · Atherosclerosis
2. Standardization of laboratory lipid profile assessment: A call for action with a special focus on the 2016 ESC/EAS dyslipidemia guidelines – Executive summary
   Pedro Marques da Silva, João Sequeira Duarte, Pedro VON HAFE, Victor Machado Gil, Jorge Nunes de Oliveira, Germano de Sousa · 2018 · Revista Portuguesa de Cardiologia
3. Prenatal biochemical screening and long term risk of maternal cardiovascular disease: population based cohort study
   Joel Geoffrey Ray, Tianhua Huang, Wendy S. Meschino, Eyal Cohen, Alison L. Park · 2018 · BMJ
4. Cardiovascular Disease Risk Across a Spectrum of Adverse Plasma Lipid Combinations by Gender and Glycemic Status
   Xiaojuan Liu, Yachao Yang, Fengling Kang, Jiqing Li, Miao Zhou, Xiaotian Ma, Tao Yu, Tao Zhang, Fuzhong Xue · 2019 · The American Journal of Cardiology
5. Rapid recommendations
   Danielle O’Toole · 2025 · Canadian Family Physician
6. Liver Injury Associated With Ezetimibe Monotherapy
   Tharsan Kanagalingam, Julieta Lazarte, David Wong, Robert Alexander Hegele · 2020 · CJC Open
7. Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines
   Nick S.R. Lan, Kharis A. Burns, Damon A. Bell, Gerald Francis Watts · 2020 · Current Opinion in Endocrinology Diabetes and Obesity
8. Different Lipid Parameters in Predicting Clinical Outcomes in Chinese Statin-Naïve Patients After Coronary Stent Implantation
   Li Zeng, Ziwei Ye, Ying Li, Yiling Zhou, Qingyang Shi, Tao Hu, Minghuan Fu, Caojie Wu, Haoming Tian, Sheyu Li · 2021 · Frontiers in Cardiovascular Medicine
9. A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome
   Donna Faye Vine, Ethan Proctor, Olivia R. Weaver, Mahua Ghosh, Katerina Maximova, Spencer D. Proctor · 2021 · Journal of the Endocrine Society
10. The impact of mobile application: "Friends of Heart" in knowledge and compliance of patients with coronary heart disease
    Riyan Pratama Putra, Ike Dhiah Rochmawati, Delta Ardy Prima · 2022 · Pharmacy Education
11. The Role of Fasting LDL-C Levels in Their Non-fasting Reduction in Patients With Coronary Heart Disease
    Qiuzhen Lin, Yan Hong Huang Fu, XueYan Zang, Qiming Liu, Ling Liu · 2021 · Frontiers in Cardiovascular Medicine
12. Moving Toward Sex-Specific Cardiovascular Risk Estimation
    Natalie Dayan, Jacob Allen Udell · 2019 · Canadian Journal of Cardiology
13. Familial Hypercholesterolemia: Awareness, Appraisal, and Action
    Jacques J. Genest · 2016 · Canadian Journal of Cardiology
14. What’s in a Number? Risk Thresholds in Different Statin Guidelines
    Christopher J. Wong, Lisa Inouye · 2017 · Journal of General Internal Medicine
15. Highlights from the Manifesto on the Health Economics of Cardiovascular Disease Prevention
    Zanfina Ademi, Sheridan E. Rodda, Karl Vivoda, Susan S. Hennessy, Olive Fenton, James S. Ware, Global Heart Hub Manifesto · 2025 · PharmacoEconomics
16. Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers
    Fangfang Wang, Dong You, Xiaoye Niu, Jack G. Shi, Ye Li, Lihang Qi, Haiyan Li · 2025 · Cardiovascular Diabetology
17. Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
    Ewelina Woźniak, Marlena Broncel, Agnieszka Woźniak, Joanna Satała, Agnieszka Pawlos, Bożena Bukowska, Paulina Gorzelak‐Pabiś · 2024 · Scientific Reports
18. Adiposity Phenotypes and Associated Cardiometabolic Risk Profile in the Inuit Population of Nunavik
    Fannie Lajeunesse‐Trempe, Marie‐Ève Piché, Paul Poirier, André Tchernof, Pierre Ayotte · 2024 · Nutrients
19. Age and sex specific thresholds for risk stratification of cardiovascular disease and clinical decision making: prospective open cohort study
    Zhe Xu, Juliet A. Usher‐Smith, Lisa A M Pennells, Ryan Chung, Matthew Arnold, Lois G. Kim, Stephen K. Kaptoge, Matthew Sperrin, Emanuele Di Angelantonio, Angela Wood · 2024 · BMJ Medicine
20. Association of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with coronary heart disease: Establishment and validation of a clinical nomogram model
    Wenlong Ding, Tao Li, Caoyang Fang, Xinxin Zhang, Enyang Wang · 2025 · Medicine
21. Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution
    Ivette Cruz‐Bautista, Yuscely Flores-Jurado, Guillermo Roa Álvarez, Mariana Salas-Aldana, Daniel Elías-López, Ricardo Federico Hernández-Franco, Sandra G. Rosales-Uvera, Arsenio Vargas‐Vázquez, Raymundo David Valdez-Echeverría, Sonia Luna del Villar Velasco et al. · 2025 · Lipids in Health and Disease
22. Exploring the relationship between NHHR and the degree of coronary artery stenosis in patients with acute coronary syndromes
    Zhenkun Yang, Yuan-Jie Li, Mingjuan Yang, Yang Xin Zi Xu, Jia Yao, Kefan Wang, Yuxia Gao · 2025 · BMC Cardiovascular Disorders
23. CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management
    G.B. John Mancini, ALICE Y.Y. CHENG, Kim Alexander Connelly, DAVID H. FITCHETT, Ronald Goldenberg, Shaun G. Goodman, Lawrence A. Leiter, Eva Lonn, Breay W. Paty, Paul Poirier et al. · 2018 · Canadian Journal of Cardiology
24. Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD
    Mustafa Al-Karaghouli, Sonia Fuentes, Tracy Davyduke, Mang Ma, Juan G. Abraldeṣ · 2022 · BMJ Open Gastroenterology
25. Moderate-intensity statin use for primary prevention for more than 5 years is associated with decreased all-cause mortality in 75 years and older
    Sun Young Kim, Hangseok Choi, Chang Won Won · 2022 · Archives of Gerontology and Geriatrics
26. Associations between insulin-like growth factor binding protein-2 and lipoprotein kinetics in men
    Chloé Rauzier, Benoı̂t Lamarche, André J. Tremblay, Patrick Couture, Frédéric Picard · 2022 · Journal of Lipid Research
27. The Effect of Biological Sex on Arterial Stiffness and Renin-Angiotensin-Aldosterone System Activity in Response to Cyclooxygenase-2 (COX-2) Inhibition
    Chantal L. Rytz, Sandra Marie Dumanski, Darlene Y. Sola, Sofia Bano Ahmed · 2022 · CJC Open
28. Undergraduate Medical Students’ Perceptions of Nutrition Education at the Northern Ontario School of Medicine
    Erica Dubois, Nicholas Ducharme, Dayna Lalonde, Lee A. Rysdale · 2022 · Canadian Journal of Dietetic Practice and Research
29. Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study
    Na Xu, Yi Yao, Lin Jiang, Jingjing Xu, Huanhuan Wang, Ying Song, Yuejin Yang, Bo Xu, Runlin Gao, Jinqing Yuan · 2022 · Thrombosis Journal
30. Supporting evidence for lipoprotein(a) measurements in clinical practice
    Anastasiya Matveyenko, Marianna Pavlyha, Gissette Reyes‐Soffer · 2023 · Best Practice & Research Clinical Endocrinology & Metabolism
31. Indian dyslipidaemia guidelines: Need of the hour
    J.P.S. Sawhney, Rajeev Gupta · 2024 · Indian Heart Journal
32. Elevated remnant cholesterol and non-HDL cholesterol concentrations from real-world laboratory results: a cross-sectional study in Southeast Asians
    Wann Jia Loh, Heng Samuel Soh, Mon Hnin Tun, Pei Ting Tan, Chin Shern Lau, Tavintharan Subramaniam, Gerald Francis Watts, Tar Choon Aw · 2024 · Frontiers in Cardiovascular Medicine
33. Association between lipoprotein (a) and risk of atherosclerotic cardiovascular disease events among maintenance hemodialysis patients in Beijing, China: a single-center, retrospective study
    Qiaojing Liang, Guojuan Zhang, Liping Jiang · 2024 · BMC Nephrology
34. Students’ beliefs, basic psychological needs, classroom participation, foreign language anxiety, and academic adjustment: A correlation study in Tashkent, Uzbekistan
    Nargiza Nuralieva, Wei Zhao, Abdo Hasan AL-Qadri, Nadia Saraa, Ming Chang · 2024 · Heliyon
35. Research in Women's Cardiovascular Health—Progress at Last?
    Karin H. Humphries, Louise Pilote · 2017 · Canadian Journal of Cardiology
36. CODAP: um consenso multidisciplinar sobre a definição, diagnóstico e tratamento da dislipidemia aterogénica em Portugal
    Alberto Mello e Silva, Carlos Aguíar, João Sequeira Duarte, Luciana Couto, Manuel Teixeira Veríssimo, Pedro Marques da Silva · 2019 · Revista Portuguesa de Cardiologia
37. Impact of changing reimbursement criteria on statin treatment patterns among patients with atherosclerotic cardiovascular disease or cardiovascular risk factors
    Chia‐Yun Hsu, Wen‐Jone Chen, Ho‐Ming Chen, Hsin‐Yi Tsai, Fei‐Yuan Hsiao · 2020 · Journal of Clinical Pharmacy and Therapeutics
38. A Snapshot of Lipid-Reporting Practices in Canadian Clinical Laboratories: An Urgent Need for Harmonisation
    Victoria Higgins, Nicole White-Al Habeeb, Allison A. Venner, Dana Bailey, Christine P. Collier, Khosrow Adeli · 2021 · Canadian Journal of Cardiology
39. Adverse Pregnancy Outcomes and Maternal Chronic Diseases in the Future: A Cross-Sectional Study Using KoGES-HEXA Data
    Geum Joon Cho, Jiae Kim, Ji Young Kim, Sung Won Han, Soo‐Bin Lee, Min‐Jeong Oh, Sa Jin Kim, Jae Eun Shin · 2022 · Journal of Clinical Medicine
40. Food behaviors accounting for the recent trends in dietary fatty acid profiles among Korean adults
    SuJin Song, Jae Eun Shim · 2022 · Nutrition Research and Practice
41. Maternal Immune Cell and Cytokine Profiles to Predict Cardiovascular Risk Six Months after Preeclampsia
    Malia S. Q. Murphy, Samantha J. Benton, Brian Cox, Kara A. Nerenberg, Scott McComb, Lakshmi Krishnan, Risini D. Weeratna, Jean‐François Paré, Alysha L. J. Dingwall‐Harvey, Shannon A. Bainbridge et al. · 2022 · Journal of Clinical Medicine
42. High-density lipoprotein cholesterol levels is negatively associated with intertrochanter bone mineral density in adults aged 50 years and older
    Pei Yang, Dongdong Li, Xiao‐Kang Li, Zongbiao Tan, Huan Wang, Xiaona Niu, Yang Han, Cheng Lian · 2023 · Frontiers in Endocrinology
43. Reference Interval for Non-HDL-Cholesterol, Remnant Cholesterol and Other Lipid Parameters in the Southern Iranian Population; Findings From Bandare Kong and Fasa Cohort Studies
    Mojtaba Farjam, Masoumeh Kheirandish, Amin Ghanbarnejad, Amin Reza Nikpoor, Azim Nejatizadeh, Teymour Aghamolaei, Mehdi Shahmoradi, Hesam Alizade, Reza Homayounfar, Hassan Zarei et al. · 2024 · Archives of Iranian Medicine
44. Apolipoprotein B vs non–high-density lipoprotein cholesterol: Association with endothelial hemostatic markers and carotid intima-media thickness
    David Karásek, H Vaverková, Ľubica Cibičková, Jaromíra Gajdová, Veronika Kučerová · 2017 · Journal of clinical lipidology
45. Clinical Utility and Practical Considerations of a Coronary Artery Disease Genetic Risk Score
    Robin Liu, Jia-Hui Cheng, Carlos U. Muzlera, John F. Robinson, Matthew R. Ban, Robert Alexander Hegele · 2019 · CJC Open
46. Outcome and Cost of Optimal Control of Dyslipidemia in Adults With High Risk for Cardiovascular Disease
    Dat T. Tran, Dan Palfrey, TKT Lo, Robert C. Welsh · 2020 · Canadian Journal of Cardiology
47. Statins for primary prevention of cardiovascular disease
    Catherine M Otto · 2016 · Heart
48. Importance of Optimization of Cardiovascular Risk Factors and Lifestyle Behaviours
    Todd J. Anderson · 2017 · Canadian Journal of Cardiology
49. Optimizing Cholesterol Management Improves the Benefits of Percutaneous Coronary Intervention
    Robert S. Rosenson, Lisandro Damián Colantonio, Sascha N. Goonewardena · 2020 · Journal of the American College of Cardiology
50. Statins and kidney health: exploring cardiovascular benefits, renal protection, and risks in chronic kidney disease
    Rahul Chikatimalla, Y. Trivedi, N. Ruhela, Shubhangi Singh, Amar Lal, Akhil Pawa, Baltej Singh, Rohit Jain · 2025 · Postgraduate medicine
51. Prediction model for recommending coronary artery calcium score screening (CAC-prob) in cardiology outpatient units: A development study
    Pakpoom Wongyikul, Apichat Tantraworasin, Pannipa Suwannasom, Tanop Srisuwan, Yutthaphan Wannasopha, Phichayut Phinyo · 2024 · PLoS ONE
52. Ărramăt : an example of Indigenous Peoples’ holistic approach of health and well-being
    Mariam Wallet Med Aboubakrine, Brenda L. Parlee, Zoé Boirin-Fargues, Alejandro Argumedo, Clint Carroll, María Eugenia Choque Quispe, Hanna Ellen Guttorm, Carwyn Jones, Irja Seurujärvi-Kari, Wasiq Silan et al. · 2025 · FACETS
53. To test, or not to test: that is the question for the future of lipoprotein(a)
    Katrina L. Ellis, Anindita Chakraborty, Eric Keith Moses, Gerald Francis Watts · 2019 · Expert Review of Cardiovascular Therapy
54. Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right
    Peter Paul Toth · 2020 · American Journal of Preventive Cardiology
55. Genosets for APOE and CYP7A1-rs3808607 variants do not predict LDL cholesterol lowering upon intervention with plant sterols in a randomized, double-blind, placebo-controlled trial
    Matthew J. Granger, Peter Eck, Itzel Vazquez‐Vidal, Maryam Shamloo, James Duncan House, Dylan MacKay · 2021 · American Journal of Clinical Nutrition
56. Rapid recommendations
    Danielle O’Toole · 2022 · Canadian Family Physician
57. The Risk of Cardiovascular Disease According to Chewing Status Could Be Modulated by Healthy Diet in Middle-Aged Koreans
    Hyejin Chun, Jongchul Oh, Miae Doo · 2022 · Nutrients
58. When Should We Measure Lipoprotein(a)?
    Karam Kostner · 2023 · Contemporary cardiology
59. Indications for omega-3 fatty acid supplementation in prevention of cardiovascular disease
    N. John Bosomworth · 2023 · Canadian Family Physician
60. The Importance of Nontraditional and Sex-Specific Risk Factors in Young Women With Vasomotor Nonobstructive vs Obstructive Coronary Syndromes
    Emilie T. Théberge, Diana N. Vikulova, Simon Neil Pimstone, Liam R. Brunham, Karin H. Humphries, Tara Sedlak · 2023 · CJC Open
61. Complexity and Management of Chronic Kidney Disease
    Pranali M. Wandile · 2023 · Open Journal of Nephrology
62. The Canadian Women’s Heart Health Alliance ATLAS on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women — Chapter 8: Knowledge Gaps and Status of Existing Research Programs in Canada
    Marie-Annick A Clavel, Harriette G.C. Van Spall, Laura E. Mantella, Heather J.A. Foulds, Varinder K. Randhawa, Monica J. E. Parry, Kiera Liblik, Amy Ashley Kirkham, Lisa M. Cotie, Shahin Jaffer et al. · 2023 · CJC Open
63. Clinical and Prognostic Value of Non-Fasting Lipoproteins and Apolipoproteins in Chinese Patients with Coronary Heart Disease
    Junfeng Jim Zhang, Zhengde Tang, Jintong Jiang, Shuying Huang, Huasu Zeng, Jun Gu, Changqian Wang, Huili Zhang · 2023 · Reviews in Cardiovascular Medicine
64. Establishing non-fasting reference values for plasma lipids levels based on age, sex, and puberty stage in a French-Canadian pediatric population
    Sophie Bouhour, Rosalie Plantefève, Virginie Gillet, Armita Abolghasemi, Fatima Zahra Bouchouirab, Andrea Baccarelli, Larissa Takser, Artuela Çaku · 2024 · Lipids in Health and Disease
65. Serum lipids as predictive markers for death by suicide
    Christopher Hyung Keun Park, D. R. Kim, Bora Kim, Sang Jin Rhee, Sung‐Joon Cho, Yong Min Ahn · 2024 · Psychiatry Research
66. Subclinical atherosclerosis in multiple sclerosis
    Ruth Ann Marrie, Ronak Patel, Stephen Allan Schaffer · 2024 · Multiple Sclerosis Journal - Experimental Translational and Clinical
67. A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system
    Jingyi Zhang, Yuting Guo, Chunyan Wei, Yan Yu, Huifang Shan, Bin Wu, Fengbo Wu · 2024 · Frontiers in Pharmacology
68. PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase
    Dahyun Park, Sungho Bea, Ji-Hwan Bae, Hyesung Lee, Young June Choe, Ju‐Young Shin, Hoon Kim · 2024 · Drugs - Real World Outcomes
69. Elderly patients with very high plasma lipoprotein(a) concentrations and few cardiovascular consequences: a case series
    Shyann Hang, Robert Alexander Hegele · 2024 · Journal of International Medical Research
70. Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients with Heterozygous Familial Hypercholesterolemia: A Meta-analysis
    Mahsa Movahedan, Ursula M. Ellis, Arden R. Barry · 2024 · American Journal of Cardiovascular Drugs
71. Drug release potential of polyacrylamide grafted-Assam Bora rice polysaccharide graft copolymer (ABRS-g-PAM) as effective controlled release polymer
    Neha Singh, Itishree Jogamaya Das, Sutapa Satpathi, Devjit Das, Bhabani Shankar Patro, Karmabeer Jena, Subhendu Chakroborty, Pankaj Dagar, Trishna Bal · 2024 · Carbohydrate Research
72. Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About Icosapent Ethyl? A Systematic Review and Meta-Analysis
    Nathália Mendes Machado, Maria Júlia Ribeiro de Oliveira, Karina Rodrigues Quesada, Jesselina Francisco dos Santos Haber, Ricardo José Tofano, Cláudio José Rubira, Tereza Laí­s Menegucci Zutin, Rosa Direito, Eliana de Souza Bastos Mazuqueli Pereira, Camila Marcondes de Oliveira et al. · 2025 · Pharmaceuticals
73. Do Oxidized Lipoproteins Cause Atherosclerotic Cardiovascular Diseases?
    Benoît J. Arsenault, Raphaëlle Bourgeois, Patrick Mathieu · 2017 · Canadian Journal of Cardiology
74. The year in cardiology 2017: prevention
    Børge Grønne Nordestgaard, Francesco Cosentino, Ulf Landmesser, Ulrich Laufs · 2017 · European Heart Journal
75. Getting Real With PCSK9 Inhibitors in Familial Hypercholesterolemia.
    A. Baass, R. Hegele · 2018 · Canadian Journal of Cardiology
76. Making Informed CHOICES: The Launch of a “Big Data” Pragmatic Trial to Improve Cholesterol Management and Prevent Heart Disease in Ontario
    Laura Legere, Anna Chu, Mohammed K. Rashid, Atul Sivaswamy, Tara O'Neill, Christine Marquez, Richelle Baddeliyanage, Sharon Elizabeth Straus, Jacob Allen Udell · 2020 · Healthcare Quarterly
77. Cardiovascular Risk Factor Modification in Asymptomatic Adults and Implications for Pilots
    I Made Ady Wirawan, Robin F. Griffiths, Peter Larsen · 2020 · Journal of UOEH
78. The Correlation Between Lipid Profile and Xanthelasma
    Puridelko Kampar · 2020 · Berkala Ilmu Kesehatan Kulit dan Kelamin
79. Non-HDL cholesterol level and depression among Canadian elderly—a cross-sectional analysis of the baseline data from the CLSA
    Jian Liu, Surim Son, Mike Giancaterino, C. Verschoor, Miya Narushima · 2020 · FACETS
80. Screening for Lipoprotein(a) Levels in Persons at Low Risk for Cardiovascular Disease
    Ludovico Furlan, Patrick M. Azcarate, Rita F. Redberg · 2021 · JAMA Internal Medicine
81. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
    2022 · PubMed Central
82. Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial
    Haiming Shi, Jingmin Zhou, Changsheng Ma, Fusui Ji, Yang Wu, Yulan Zhao, Jun Qian, Xiaolong Wang · 2022 · Frontiers in Cardiovascular Medicine
83. Lp(a) does not affect intima media thickness in hypercholesterolemic children –a retrospective cross sectional study
    Oliver Helk, Andreas Böck, Claudia Stefanutti, Kurt Widhalm · 2022 · Atherosclerosis Plus
84. Adherence to Cardiovascular Prevention Guidelines in an Academic Centre
    Iness Soltani, Marie-Claude Beaulieu, Maude Sestier, Hao Cheng Shen, Ali Hillani, Alexis Matteau, Samer Mansour, Brian James Potter · 2023 · CJC Open
85. A bibliometric analysis and visualization of literature on non-fasting lipid research from 2012 to 2022
    Yilin Hou, Zehua An, Xiaoyu Hou, Yunpeng Guan, Guangyao Song · 2023 · Frontiers in Endocrinology
86. Pharmacotherapeutics for dyslipidemia management
    Mohamed Toufic El Hussein, Aditi Sharma, Komal Parmar, Krupa Shelat · 2023 · The Nurse Practitioner
87. Factors to consider with estimated low-density lipoprotein cholesterol using the new Sampson/NIH equation
    Samantha M. Logan, Rajeevan Selvaratnam · 2023 · Clinical Biochemistry
88. The LIPL study: Postprandial lipid profile, inflammation, and platelet activity in patients with chronic coronary syndrome
    Edita Pogran, Paul Michael Haller, Claudia Wegberger, Maximilian Tscharre, Irena Vujasin, Christoph Clemens Kaufmann, Petra Dick, Bernhard Jäger, Johann Wojta, Kurt Huber · 2023 · Atherosclerosis Plus
89. Exploring Utilization and Establishing Reference Intervals for the Apolipoprotein B Test in the Korean Population
    Rihwa Choi, Sang Gon Lee, Eun Hee Lee · 2023 · Diagnostics
90. The Role of Remnant Cholesterol Beyond Low-Density Lipoprotein Cholesterol in Arterial Stiffness: A Cross-Sectional Study
    Peng Zhang, Jinfeng Ma, Daojing Li, Qiuhua Li, Ziyou Qi, Peng Xu, Lixia Liu, Hongfang Li, Aimei Zhang · 2023 · Metabolic Syndrome and Related Disorders
91. Associations of dietary iron intake with cardiovascular disease risk and dyslipidemia among Chinese adults
    Min Cui, Hao Wu, Hanmo Zhang, Liping Wei, Xin Qi · 2024 · Lipids in Health and Disease
92. Comparing the Effect of Combining Exercise with Rosuvastatin versus Atorvastatin on Lipid Profile and Functional Capacity: A Retrospective Cohort Study
    Sherif Eltonsy, Monique Dufour Doiron, Patrice Simard, Caroline José, Martin Sénéchal, Danielle R. B̀ouchard, Rémi LeBlanc, Mathieu F. Bélanger · 2020 · BioMed Research International
93. A cautionary tale: Is this APOB whole-gene duplication actually pathogenic?
    Julieta Lazarte, Amanda J. Berberich, Jian Wang, Robert Alexander Hegele · 2020 · Journal of clinical lipidology
94. The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk
    Fernando Yue Cesena, Antônio Gabriele Laurinavicius, Viviane A. Valente, Raquel Conceição, Raul Dias Santos, Márcio Sommer Bittencourt · 2017 · Arquivos Brasileiros de Cardiologia
95. TEN-YEAR STATIN ADHERENCE IN SURVIVORS OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE AMI-QUEBEC STUDY
    Thao Thanh Huynh, P Lecca, Martine Montigny, R Gagnon, Mark Jeffrey Eisenberg, Claude Lauzon, Samer Mansour, Stéphane Rinfret, Marc Afilalo, Michel T Nguyen et al. · 2018 · Journal of Population Therapeutics and Clinical Pharmacology
96. Monitoring patients with systemic lupus erythematosus: general characteristics and discussion questions (according to the Canadian Rheumatology Association recommendations)
    T. A. Panafidina, Т. В. Попкова, Sergey K. Solovyev · 2019 · Rheumatology Science and Practice
97. Use of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists
    Arden R. Barry, William Semchuk, Ann Thompson, Marlys H. LeBras, Sheri L. Koshman · 2020 · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
98. Lignes directrices simplifiées de PEER sur les lipides : actualisation 2023
    Michael R. Kolber, Scott W Klarenbach, Michel Cauchon, Mike Cotterill, Loren D. Regier, Raelene Marceau, Norah Duggan, Rebecca Whitley, Alex S. Halme, Tanis Poshtar et al. · 2023 · Canadian Family Physician
99. The Cardiovascular Burden of Undiagnosed Familial Hypercholesterolemia: Need to Modify Guidelines to Encourage Earlier Diagnosis and Therapy
    Ruth McPherson · 2018 · Canadian Journal of Cardiology
100. Non-Fasting Triglyceride Levels as a Superior Predictor of Cardiovascular Disease
     Hyemoon Chung, Weon Kim · 2020 · Circulation Journal